Research programme: cancer therapeutics - TFC Therapeutics
Latest Information Update: 16 Feb 2024
At a glance
- Originator TFC Therapeutics
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer